Add like
Add dislike
Add to saved papers

SU-F-T-37: Dosimetric Evaluation of Planned Versus Decay Corrected Treatment Plans for the Treatment of Tandem-Based Cervical HDR Brachytherapy.

Medical Physics 2016 June
PURPOSE: This study evaluated dosimetric parameters for actual treatment plans versus decay corrected treatment plans for cervical HDR brachytherapy.

METHODS: 125 plans of 25 patients, who received 5 fractions of HDR brachytherapy, were evaluated in this study. Dose was prescribed to point A (ICRU-38) and High risk clinical tumor volume (HR-CTV) and organs at risk (OAR) were, retrospectively, delineated on original CT images by treating physician. First HDR plan was considered as reference plan and decay correction was applied to calculate treatment time for subsequent fractions, and was applied, retrospectively, to determine point A, HR-CTV D90, and rectum and bladder doses.

RESULTS: The differences between mean point A reference doses and the point A doses of the plans computed using decay times were found to be 1.05%±0.74% (-2.26% to 3.26%) for second fraction; -0.25%±0.84% (-3.03% to 3.29%) for third fraction; 0.04%±0.70% (-2.68% to 2.56%) for fourth fraction and 0.30%±0.81% (-3.93% to 2.67%) for fifth fraction. Overall mean point A dose difference, for all fractions, was 0.29%±0.38% (within ± 5%). Mean rectum and bladder dose differences were calculated to be -3.46%±0.12% and -2.47%±0.09%, for points, respectively, and -1.72%±0.09% and -0.96%±0.06%, for D2cc, respectively. HR-CTV D90 mean dose difference was found to be -1.67% ± 0.11%. There was no statistically significant difference between the reference planned point A doses and that calculated using decay time to the subsequent fractions (p<0.05).

CONCLUSION: This study reveals that a decay corrected treatment will provide comparable dosimetric results and can be utilized for subsequent fractions of cervical HDR brachytherapy instead of actual treatment planning. This approach will increase efficiency, decrease workload, reduce patient observation time between applicator insertion and treatment delivery. This would be particularly useful for institutions with limited resources or large patient populations with limited access to care.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app